trending Market Intelligence /marketintelligence/en/news-insights/trending/x-cAJ0spT0WL2x349afhVg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca Q3 earnings up 40% YOY; 2019 sales outlook raised anew

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AstraZeneca Q3 earnings up 40% YOY; 2019 sales outlook raised anew

AstraZeneca PLC said third-quarter 2019 earnings grew year over year and raised 2019 sales guidance for a second consecutive quarter.

The Cambridge, U.K.-based drugmaker reported third-quarter core EPS of 99 cents, up 40% from a year earlier.

The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter was $1.02.

On a reported basis, EPS was 23 cents, down 33% from the year-ago quarter.

AstraZeneca's core operating profit increased 43% year over year to $1.88 billion.

Total revenue for the quarter totaled $6.41 billion, up 20% from the prior-year period. Product sales came in at $6.13 billion, a 16% increase from the same year-ago quarter, mainly driven by cancer drugs, biopharmaceuticals and respiratory medicines.

For the first nine months of 2019, AstraZeneca's core EPS rose 39% year over year to $2.61. Core operating profit for the period was $4.89 billion, reflecting a 41% growth from 2018.

Total revenue for the period ended Sept. 30 amounted to $17.72 billion, a 13% year-over-year increase. Meanwhile, product sales for the same period rose 13% on an annual basis to $17.32 billion.

Nine-month reported EPS was 79 cents, a decline of 11% from the year-ago period.

AstraZeneca raised its full-year sales guidance for the second time, citing the strong performance of its new medicines.

The British pharmaceutical company now expects product sales to grow by a low to mid-teens percentage at constant exchange rates, from the previous estimate of low double-digit percentage increase.

AstraZeneca maintains its core EPS guidance of $3.50 to $3.70 for the full year.

The S&P Global Market Intelligence consensus normalized EPS estimate for 2019 is $3.57.